List of Nevanac drug patents
Nevanac is owned by Novartis.
Nevanac contains Nepafenac.
Nevanac has a total of 3 drug patents out of which 0 drug patents have expired.
Nevanac was authorised for market use on 19 August, 2005.
Nevanac is available in suspension/drops;ophthalmic dosage forms.
Nevanac can be used as method of treating ocular inflammation.
The generics of Nevanac are possible to be released after 31 January, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071648 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US8324281 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US7834059 | NOVARTIS | Topical nepafenac formulations |
Jan, 2027
(3 years from now) | |
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
NEVANAC family patents
5
United States
2
Japan
1
South Africa
1
Denmark
1
Austria
1
Mexico
1
Australia
1
Hong Kong
1
Russia
1
Slovenia
1
Uruguay
1
Germany
1
Argentina
1
Brazil
1
Portugal
1
Cyprus
1
Spain
1
Korea, Republic of
1
Poland
1
Taiwan, Province of China
1
China
1
Canada
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic